MedTrace Logo

Biomarker and Thrombogenicity Assessment in Cardiopulmonary Bypass Surgery Utilizing Acute Normovolemic Hemodilution

NCT03326323 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 43

Last updated 2020-01-13

Study results available
· View outcomes & findings →

Summary

This study will help enhance current understanding of the impact of Acute Normovolemic Hemodilution (ANH) administration on transfusion requirements post cardiac surgery, the effect of this procedure on coagulation, and platelet hemostasis, and the amount of chest tube drainage 24 hours post coronary artery bypass graft surgery (CABG) surgery.

Conditions

  • Bleeding Reduction

Interventions

PROCEDURE

Acute Normovolemic Hemodilution

Collection and reinfusion of a patients own blood during coronary artery bypass graft surgery.

Sponsors & Collaborators

  • Instrumentation Laboratory

    collaborator INDUSTRY

  • Inova Health Care Services

    lead OTHER

Principal Investigators

  • Eric L Sarin, MD · Inova Heart and Vascular Institute

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-19
Primary Completion
2019-09-17
Completion
2019-10-17

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03326323 on ClinicalTrials.gov